[go: up one dir, main page]

DE69903229D1 - Verwendung der Leserahmen der adenoviralen E4-Region zur Verbesserung der Genexpression - Google Patents

Verwendung der Leserahmen der adenoviralen E4-Region zur Verbesserung der Genexpression

Info

Publication number
DE69903229D1
DE69903229D1 DE69903229T DE69903229T DE69903229D1 DE 69903229 D1 DE69903229 D1 DE 69903229D1 DE 69903229 T DE69903229 T DE 69903229T DE 69903229 T DE69903229 T DE 69903229T DE 69903229 D1 DE69903229 D1 DE 69903229D1
Authority
DE
Germany
Prior art keywords
expression
region
adenoviral
improve
gene expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69903229T
Other languages
English (en)
Other versions
DE69903229T2 (de
Inventor
Majid Mehtali
Monika Lusky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Application granted granted Critical
Publication of DE69903229D1 publication Critical patent/DE69903229D1/de
Publication of DE69903229T2 publication Critical patent/DE69903229T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/44Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
DE69903229T 1998-07-07 1999-07-01 Verwendung der Leserahmen der adenoviralen E4-Region zur Verbesserung der Genexpression Expired - Lifetime DE69903229T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98401722 1998-07-07
EP98402825 1998-11-13

Publications (2)

Publication Number Publication Date
DE69903229D1 true DE69903229D1 (de) 2002-11-07
DE69903229T2 DE69903229T2 (de) 2003-06-26

Family

ID=26151663

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69914382T Expired - Fee Related DE69914382T2 (de) 1998-07-07 1999-07-01 Verwendung der Leserahmen der adenoviralen E4-Region zur Verbesserung der Genexpression
DE69903229T Expired - Lifetime DE69903229T2 (de) 1998-07-07 1999-07-01 Verwendung der Leserahmen der adenoviralen E4-Region zur Verbesserung der Genexpression

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69914382T Expired - Fee Related DE69914382T2 (de) 1998-07-07 1999-07-01 Verwendung der Leserahmen der adenoviralen E4-Region zur Verbesserung der Genexpression

Country Status (11)

Country Link
US (1) US6475480B1 (de)
EP (2) EP0974668B1 (de)
JP (1) JP2000106875A (de)
AT (2) ATE225400T1 (de)
AU (1) AU756607B2 (de)
CA (1) CA2276791A1 (de)
DE (2) DE69914382T2 (de)
DK (2) DK0974668T3 (de)
ES (2) ES2180258T3 (de)
HK (1) HK1043390A1 (de)
PT (2) PT1199368E (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225113B1 (en) * 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
AU2001265154A1 (en) * 2000-05-31 2001-12-11 Genvec, Inc. Method and composition for targeting an adenoviral vector
EP1203819A3 (de) 2000-10-06 2002-08-07 Transgene S.A. Entzündungshemmende Vektoren
EP1539937A4 (de) * 2002-08-22 2006-07-26 Merck & Co Inc Verfahren zur vermehrung von adenovirus und damit produziertes virus
CA2678736A1 (en) 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional il-2 - il-18 fusion proteins
CN101128593B (zh) * 2004-12-31 2014-09-03 佩尔·松内·霍尔姆 逆转动物细胞中多种抗性的方法
WO2008073893A2 (en) * 2006-12-08 2008-06-19 Adv Technologies Llc Methods for producing an adenovirus type 5 gene transfer vector
US8465732B2 (en) 2007-01-19 2013-06-18 Cornell Research Foundation, Inc. Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof
BR112013003579A2 (pt) 2010-08-16 2016-06-07 Salk Inst For Biological Studi adenovírus, células, e, métodos para tratar câncer
KR101522341B1 (ko) * 2012-10-02 2015-05-21 국립암센터 신규한 조건부-복제 가능 아데노바이러스 및 그의 제조 방법
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Gm−csfとil−4のコンジュゲート、組成物、ならびにそれに関連する方法
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
CN117384961A (zh) 2016-02-23 2024-01-12 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3541420A2 (de) 2016-11-16 2019-09-25 Immunomic Therapeutics, Inc. Nukleinsäuren zur behandlung von allergien
EP3532082A4 (de) 2016-12-12 2020-08-26 Salk Institute for Biological Studies Auf tumoren gerichtete synthetische adenoviren und verwendungen davon
EP4512477A3 (de) 2017-04-22 2025-06-11 Immunomic Therapeutics, Inc. Verbesserte lampenkonstruktionen
KR20200016224A (ko) 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
SG11201910101SA (en) 2017-05-08 2019-11-28 Gritstone Oncology Inc Alphavirus neoantigen vectors
EP3775175A4 (de) 2018-04-09 2022-02-09 Salk Institute for Biological Studies Onkolytische adenoviruszusammensetzungen mit verbesserten replikationseigenschaften
EP3793595A1 (de) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Verbesserte lamp-konstrukte mit allergenen
TWI856108B (zh) * 2019-05-30 2024-09-21 美商磨石生物公司 經修飾之腺病毒
AU2020366515A1 (en) 2019-10-18 2022-04-21 Immunomic Therapeutics, Inc. Improved lamp constructs comprising cancer antigens
CN110714027A (zh) * 2019-10-28 2020-01-21 嘉铭(固安)生物科技有限公司 一种表达质粒、用于包装二代腺病毒的细胞株及其应用
CN110656090B (zh) * 2019-10-28 2023-06-30 嘉兴安宇生物科技有限公司 一种表达质粒、用于包装容量增加的二代腺病毒的细胞株及其应用
US20250177509A1 (en) * 2020-07-06 2025-06-05 Jiaxing Anyu Biotechnology Co., Ltd Recombinant adenovirus vaccine for african swine fever and method for constructing same
EP4242318A4 (de) 2021-01-21 2024-02-14 Cellid Co., Ltd Neuer adenovirusvektor ohne replikationskompetentes adenovirus und verwendung davon
AU2023254186A1 (en) 2022-04-10 2024-10-17 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
EP0911413A3 (de) * 1992-12-03 2000-11-15 Genzyme Corporation Mindestadenovirus-Vector zur Gentherapie
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6110744A (en) * 1996-11-13 2000-08-29 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement
US5981275A (en) * 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
US6100086A (en) 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems

Also Published As

Publication number Publication date
CA2276791A1 (en) 2000-01-07
DE69914382D1 (de) 2004-02-26
ATE258228T1 (de) 2004-02-15
ES2180258T3 (es) 2003-02-01
US6475480B1 (en) 2002-11-05
JP2000106875A (ja) 2000-04-18
ES2210081T3 (es) 2004-07-01
DK1199368T3 (da) 2004-04-13
PT1199368E (pt) 2004-04-30
DE69903229T2 (de) 2003-06-26
HK1043390A1 (en) 2002-09-13
ATE225400T1 (de) 2002-10-15
EP1199368A3 (de) 2002-07-17
AU3800999A (en) 2000-06-08
DE69914382T2 (de) 2004-11-04
EP0974668B1 (de) 2002-10-02
EP0974668A1 (de) 2000-01-26
AU756607B2 (en) 2003-01-16
EP1199368A2 (de) 2002-04-24
DK0974668T3 (da) 2002-11-11
EP1199368B1 (de) 2004-01-21
PT974668E (pt) 2003-01-31

Similar Documents

Publication Publication Date Title
DE69914382D1 (de) Verwendung der Leserahmen der adenoviralen E4-Region zur Verbesserung der Genexpression
IL234063A (en) Adenovirus containing capsid aavrh.34 and a heterologous gene, its preparation and preparations containing it
EP0851769A4 (de) Gentherapie mit hilfe von schaf-adenoviralen vektoren
WO2001083692A3 (en) Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
DE69941823D1 (de) Eine verbesserte methode zur herstellung und reinigung von adenoviralen vektoren
PH12016500338A1 (en) Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
ATE348155T1 (de) Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
WO2006116267A3 (en) Cell-specific molecule and method for importing dna into osteoblast nuclei
WO2021247995A3 (en) Compositions and methods of treating neuropathic pain
CA2167578A1 (en) Chicken anemia virus mutants and vaccines and uses based on the viral proteins vp1, vp2 and vp3 or sequences of that virus coding therefor
SG142300A1 (en) Promoters for expression in modified vaccinia virus ankara
WO2005109026A3 (en) Magnet structure for mri apparatus and mri apparatus
EP0752888A4 (de) NUKLEOTID- AMINOSÄURESEQUENZEN DER HERPEVIREN gB,gC UND gD AUS HUND UND IHRE VERWENDUNGEN
ATE161049T1 (de) Verfahren und nukleinsäuresequenzen zur expression des zellulose-synthase-operons
WO2003031633A3 (de) Adenovirales vektorsystem
CHEN et al. STUDY OF GENES DIFFERENTIALLY EXPRESSED IN CD34~+ CELLS FROM G-CSF-MOBILIZED PERIPHERAL BLOOD AND BONE MARROW USING THE TECHNIQUE OF SUPPRESSION SUBTRACTIVE HYBRIDIZATION
XIAO et al. STUDY OF TT VIRUS IN EXPERIMENTALLY INFECTED RHESUS MONKEY
MA et al. Expression of Mage-A1, A2, A3 in breast cancer tissue and breast cancer cell lines
ZHANG et al. SCREENING AND CLONING OF THE GENES OF PROTEIN INTERACTING WITH THE NONSTRUCTURAL PROTEIN 5B OF HEPATITIS C VIRUS
SUN et al. Development of packageable replication-defective HBV mutants and experimental study on their anti-HBV effects by expressing antisense RNA
ZHUANG et al. Relationship between genetic diversity of surface protein of Streptococcus mutans and dental caries. Ⅱ Sequence of V-region and P-region gene of surface protein of Streptococcus mutans
LIU et al. Protective effects of bcl-2 gene against lung ischemia-reperfusion injury
WO2004060912A3 (en) Chimeric capsid proteins and expression vectors for monocistronic expression of multiple genes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition